Selected highlights from the European Academy of Neurology annual meeting, Vienna, Austria, June 25-28, 2022.
June 30 Edition
June 28 Edition
COVID vaccine response with ofatumumab
Delayed time to wheelchair with siponimod
HSCT – the Swiss experience
Vaccine response to BTK inhibitors
Clinical tip of the day
Read More
Selected highlights from the European Academy of Neurology annual meeting, Vienna, Austria, June 25-28, 2022.
June 30 Edition
June 29 Edition
Relapses uncommon after COVID vaccination
The aging MS patient
Ocrelizumab EID
Natalizumab EID
Clinical tip of the day
Read More
A fourth revision of the McDonald diagnostic criteria is currently underway to address some of the conceptual and practical difficulties in the diagnosis of multiple sclerosis, according to Dr. Jeffrey Cohen, Cleveland Clinic, Cleveland, Ohio. His remarks were made at the 43rd International Neuroscience Symposium of the Université de Montréal, held May 3-5, 2022, in Montreal. Read More
Recent imaging studies in multiple sclerosis have focused on the association between cognitive dysfunction and grey-matter tissue loss, most notably of the cerebral cortex and thalamus. For example, at the American Academy of Neurology annual meeting, an analysis of the SPRINT-MS trial proposed that lower thalamic volume at baseline may be a useful predictor of physical, cognitive and visual disability in progressive MS (Nicholson et al. AAN 2022;S12.007). Thalamic volume at the time of relapse may also be predictive of cognitive recovery as assessed by the Symbol Digit Modalities Test (SDMT) (Weinstock et al. AAN 2022;P14.010). As such, thalamic volume (but not T2 lesion volume in this study) may serve as a marker of cognitive reserve. Read More
Click here to take the survey on Improving PMS outcomes.
Canadian researchers have proposed six criteria that must be met for a disease-modifying therapy (DMT) to be effective in progressive multiple sclerosis (Yong & Yong. Nat Rev Neurol 2022;18:40-55). Over a dozen DMTs are currently available but they generally have limited effectiveness in slowing the neurodegeneration that underlies disability progression.